Abels 1993.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 124, hematological malignancies, genitourinary, gastrointestinal, other cancer; no anticancer therapy
Interventions	drug = Epoetin alpha dose = 100 IU/kg sc TIW hb‐target = not reported planned ESA duration = 8 weeks
Outcomes	Primary: transfusion, Hct; secondary: QoL, safety
Notes	study number = 98906
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	computer‐generated
Allocation concealment?	Unclear risk	each patient was assigned a random identification number and was assigned to a treatment group by a computerized randomization schedule